Affymetrix Launches New Publication for Microarray Research; Website Features Articles on All Aspects of Microarray-Based Exper
July 10 2006 - 7:00AM
Business Wire
Affymetrix Inc. (NASDAQ:AFFX) announced today the launch of the
Affymetrix UserForum, an online magazine featuring weekly updates
on new technology, analyses, services, and training. The magazine
will help scientists perform fast and successful GeneChip(R)
microarray experiments. The UserForum provides an interactive
community where Affymetrix customers can learn about new products
and services, explore emerging applications, and share research
challenges and success stories. The website offers feature
articles, video interviews, and live web talks with interactive
question-and-answer sessions. Topics covered include software
tools, third-party providers, and collaboration updates, such as
the 500K Control Program. "Affymetrix microarray users will learn
about the very latest tools and applications that can help them
plan and perform their GeneChip-based research in the lab," said
Bronwyn Barnett, managing editor of UserForum. "The UserForum
focuses on the whole product solution from the initial study design
to the final data analysis. The content will help accelerate
discovery by enabling customers to quickly select the right tools
and services for the job." UserForum is a sister publication to the
Affymetrix Microarray Bulletin (AMB), a print and online magazine
featuring interviews with scientists discussing their most recent
discoveries based on microarray research. To visit the Affymetrix
UserForum and to register for regular email updates, please visit:
www.affymetrix.com/userforum/index.uf. Current UserForum articles
and video interviews include: Collaboration to Create Control
Cohort Databases for Affymetrix 500K Human Mapping Array Set
Affymetrix is collaborating with researchers at the National Genome
Research Network in Germany, GlaxoSmithKline, Erasmus MC, the
Karolinska Institute, and others to create a new publicly available
control cohort database for the Affymetrix 100K and 500K Human
Mapping Array sets. To watch this UserForum video, please visit:
www.affymetrix.com/userforum/news/collaborations/schreiber.uf The
Broad Institute's Mark Daly Discusses the Haploview Software Tool
for Association Studies Mark Daly, Ph.D., and his team at the Broad
Institute have developed a new software program, called Haploview,
for analyzing linkage disequilibrium and haplotype patterns in
genotype data sets comprising up to tens of thousands of SNPs in
thousands of individuals. To watch this UserForum video, please
visit: www.affymetrix.com/userforum/analysis/statistics/daly1.uf
Duke and Affymetrix Sign Five-Year Translational Medicine Agreement
Duke's Joe Nevins and Geoff Ginsburg outline their formula for
translational medicine success. To read this UserForum article,
please visit:
www.affymetrix.com/userforum/news/collaborations/duke.uf About AMB
AMB is an online and print magazine published by Affymetrix that
highlights leading microarray research and diagnostic development
from around the world. AMB features interviews by and for
scientists, statisticians and software engineers--one expert
interviewing another. Our goal is to create a forum where this
community can discuss research and share new resources and
information. AMB print and video interviews, as well as archived
scientific seminars, can be found at: www.microarraybulletin.com.
About Affymetrix Affymetrix scientists invented the world's first
microarray in 1989 and began selling the first commercial
microarray in 1994. Since then, Affymetrix GeneChip(R) technology
has become the industry standard in molecular biology research.
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic and biotechnology companies as well as leading academic,
government and not-for-profit research institutes. More than 1,400
systems have been installed around the world and nearly 4,000
peer-reviewed papers have been published using the technology.
Affymetrix' patented photolithographic manufacturing process
provides the most information capacity available today on an array,
enabling researchers to use a whole-genome approach to analyzing
the relationship between genetics and health. Affymetrix is
headquartered in Santa Clara, Calif., with subsidiaries in Europe
and Asia, as well as manufacturing facilities in Sacramento,
Calif., and Bedford, Mass. The company has about 1,000 employees
worldwide. For more information about Affymetrix, please visit the
company's Web site at www.Affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: uncertainties
relating to the success of the UserForum magazine and publication
initiatives discussed in this press release; risks of the Company's
ability to achieve and sustain higher levels of revenue, higher
gross margins, reduced operating expenses; uncertainties relating
to technological approaches, manufacturing (including risks related
to the Company's ability to achieve hoped-for manufacturing yields
for certain array products, including the ability to identify and
resolve manufacturing problems), product development; personnel
retention; uncertainties related to cost and pricing of Affymetrix
products; dependence on collaborative partners; uncertainties
relating to sole source suppliers; uncertainties relating to FDA
and other regulatory approvals; competition; risks relating to
intellectual property of others and the uncertainties of patent
protection and litigation. These and other risk factors are
discussed in Affymetrix' Form 10-K for the year ended December 31,
2005, and other SEC reports, including its Quarterly Reports on
Form 10-Q for subsequent quarterly periods. Affymetrix expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Affymetrix' expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. NOTE: Affymetrix, the
Affymetrix logo, and GeneChip are registered trademarks owned or
used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024